• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Curable CEO Dr. Lisa Boyette named a 2016 PharmaVOICE 100 honoree

Curable CEO Dr. Lisa Boyette named a 2016 PharmaVOICE 100 honoree

August 3, 2016
CenterWatch Staff

Curable, a nonprofit research accelerator that applies engineering approaches to medicine to develop solutions for rare diseases, has announced that its chief executive officer Lisa Boyette, M.D., Ph.D., has been named a 2016 PharmaVOICE 100 honoree. The PharmaVOICE 100 is an annual list of inspirational and innovative individuals recognized for their positive contributions to the life-sciences industry.

“I am proud to join such distinguished colleagues in the 2016 PharmaVOICE 100,” said Dr. Boyette. “We founded Curable in 2014 to accelerate medical research and develop a cure for primary sclerosing cholangitis (PSC) in time to save the life of my brother Jon and other patients with this disease. Thanks to our team’s dedication and determination, we are making great strides toward our goal of getting new therapeutic options and an early diagnostic for PSC in phase II clinical trials in five years.”

“Dr. Lisa Boyette is smart, resolute and resourceful; she is a force of nature,” said Dietrich A. Stephan, PhD, who is chairman of Curable and also chairman of the Department of Human Genetics at the University of Pittsburgh. “She has brought together all the PSC stakeholders—researchers, patients, clinicians, investors and scientists—in a coordinated effort, and is leveraging resources and expertise from academia, government, and industry to break down barriers and make rapid progress toward effective therapies for the disease. Based on Dr. Boyette’s leadership and Curable’s early success, the organization is now expanding its scope to serve all patients with a rare disease.”

PharmaVOICE 100 honorees have inspired or motivated their colleagues, peers, and even competitors; have affected positive changes in their own organizations through innovative and game-changing strategies and thinking; and given back to their communities and other philanthropic causes.

PSC is an autoimmune disease of the bile ducts that leads to liver failure. There are about 50,000 patients with PSC in the U.S. today. No one knows what causes this disease, and there are currently no effective medical therapies.

Upcoming Events

  • 25Apr

    Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

  • 26Apr

    FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

  • 27Apr

    Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

  • 17May

    2023 WCG Avoca Quality Consortium Summit

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Five Ws

    Consider the Five ‘W’s to Understand Potential Participants

  • QandA-360x240.png

    Perspectives from Smaller-Sized CROs: Q&A with Cheryle Evans

  • White House

    Trial Stakeholders Advise White House on Emergency Research Infrastructure

  • SurveywBlueBackground-360x240.png

    Stress Levels Continue to Climb in Healthcare Workforce, Survey Finds

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing